Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes

By sjmartinez • May 7, 2025

Ferrante ND, Hubbard RA, Weinfurtner K, Mezina AI, Newcomb CW, Furth EE, Bhattacharya D, Njei B, Taddei TH, Singal A, Hoteit MA, Park LS, Kaplan D, Lo Re V 3rd. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiol Drug Saf. 2025 May;34(5):e70154. doi: 10.1002/pds.70154. PMID: 40328444.

Tags: Cholangiocarcinoma, Infectious Diseases, liver cancer, Outcomes, Publications, validation studies, Veterans Administration

Secretion of the Francisella pathogenicity island effector protein PdpE requires components of both the Sec and Type IV pilus secretion pathways

Lee B-Y, Clemens DL, Horwitz MA. Secretion of the Francisella pathogenicity island effector protein PdpE requires components of both the Sec and Type IV pilus secretion pathways.[...]

Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum

Dong HV, Salem GM, Kerin T, Tang KH, Cortado R, Shin-Sim M, Arnold EM, Swendeman D, Tobin NH, Rimoin AW, Aldrovandi GM, Yang OO, Bryson[...]

MUCOR-ADVANCE: Uniting multidisciplinary science to defeat a deadly fungus

Wurster S, Stewart AG, Gu Y, Youssef EG, John TM, Uppuluri P, Chamilos G, Filler S, Bruno V, Ibrahim AS, Kontoyiannis DP; MUCOR-ADVANCE consortium. MUCOR-ADVANCE:[...]